ASBM Quoted in FDA Week Story on Naming
September 7, 2012
ASBM Executive Director Michael Reilly was quoted in the FDA Week story Stakeholders Draw Biosimilar Naming Insight From Biologic Approval. Read the article.
Latest News
Dr. Dolinar Presents at Florida Association of Health Plans
September 6, 2012
On September 6, Dr. Dolinar presented an overview of biologics and biosimilars at the Florida Association of Health Plans Annual Conference. View his FAHP Presentation
ASBM to Host Roundtables on Physician Notification
July 24, 2012
The Alliance for Safe Biologic Medicines (ASBM) will host a series of roundtables beginning in September to seek input from the patient, physician and pharmacist communities on the issue of physician notification for biosimilars. The roundtables seek to build on the May 24th ASBM Advisory Board physician notification working group meeting led by Chairman Richard […]
Forbes: FDA Balances Costs, Patient Safety in the Biologics and Personalized Medicine
July 23, 2012
Good piece on biosimilars in Forbes by Jon Entine, Senior Fellow at the Center for Health & Risk Communication at George Mason University. Read FDA Balances Costs, Patient Safety in the Biologics and Personalized Medicine
President Obama Signs FDA User Fee Bill
July 10, 2012
On July 9, President Obama signed the bipartisan Food and Drug Administration Safety and Innovation Act, that reauthorizes FDA user fees and that will establish new user-fee programs for biosimilar drugs. Read more.
Alliance for Safe Biologic Medicines Responds to Supreme Court Decision
June 28, 2012
WASHINGTON – Dr. Richard Dolinar, chairman of the Alliance for Safe Biologic Medicines (ASBM) issued the following statement in response to the Supreme Court ruling on the Affordable Care Act and its impact on the Food and Drug Administration’s (FDA) creation of a biosimilar pathway. “As biosimilar medicines are introduced into the U.S. in the […]
Alliance for Safe Biologic Medicines Responds to Supreme Court Decision
June 28, 2012
WASHINGTON – Dr. Richard Dolinar, chairman of the Alliance for Safe Biologic Medicines (ASBM) issued the following statement in response to the Supreme Court ruling on the Affordable Care Act and its impact on the Food and Drug Administration’s (FDA) creation of a biosimilar pathway. “As biosimilar medicines are introduced into the U.S. in the […]
ASBM Advisory Board Members Convene on Physician Notification
June 25, 2012
ASBM Chairman Dr. Richard Dolinar convened a working group of Advisory Board members to discuss the elements of a physician notification policy for biosimilars that prioritizes patient safety.
ASBM Advisory Board Members Convene on Physician Notification
June 25, 2012
ASBM Chairman Dr. Richard Dolinar convened a working group of Advisory Board members to discuss the elements of a physician notification policy for biosimilars that prioritizes patient safety.
ASBM Advisory Board Members Convene on Physician Notification
June 18, 2012
ASBM Chairman Dr. Richard Dolinar convened a working group of Advisory Board members to discuss the elements of a physician notification policy for biosimilars that prioritizes patient safety. Read the summary.
